Protocol Page


	Study ID (Protocol Number)
	AI444-026


	STUDY LOCATIONS*
	Alamo Medical Research San Antonio, TX 78215 Recruiting	Dean Clinic Madison, WI 53715 Recruiting
	Baylor College Of Medicine Houston, TX 77030 Recruiting	Digestive Disease Associates, P.A. Baltimore, MD 21229 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
	STUDY OVERVIEW
	The purpose of this study is to provide anti-HCV drugs to +/- 200 subjects treated in prior BMS studies with placebo + Peginterferon Alfa-2a and Ribavirin and determine if the addition of these drugs can result in higher cure rates in patients who previously failed therapy. Approximately 100 genotype 1b subjects rolling over from BMS study AI447-028 who received placebo will be treated with active drugs in this study.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.